Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 254

1.

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.

PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019.

2.

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.

J Rheumatol. 2019 Jan 15. pii: jrheum.171034. doi: 10.3899/jrheum.171034. [Epub ahead of print]

PMID:
30647182
3.

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.

Harrold LR, Reed GW, Best J, Zlotnick S, Kremer JM.

Rheumatol Ther. 2018 Dec;5(2):507-523. doi: 10.1007/s40744-018-0127-1. Epub 2018 Oct 6.

4.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.

Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182.

5.

Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.

Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.

J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.

6.

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry.

Pappas DA, Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA.

Am Health Drug Benefits. 2018 May;11(3):148-158.

7.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669
8.

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.

Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J.

Clin Rheumatol. 2018 Aug;37(8):2275-2280. doi: 10.1007/s10067-018-4140-0. Epub 2018 Jun 4.

9.

Elevated atmospheric carbon dioxide concentrations promote ant tending of aphids.

Kremer JMM, Nooten SS, Cook JM, Ryalls JMW, Barton CVM, Johnson SN.

J Anim Ecol. 2018 Sep;87(5):1475-1483. doi: 10.1111/1365-2656.12842. Epub 2018 May 17.

PMID:
29700820
10.

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.

Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25.

PMID:
29696436
11.

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.

Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M.

Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14.

PMID:
29575803
12.

Transcriptome landscape of a bacterial pathogen under plant immunity.

Nobori T, Velásquez AC, Wu J, Kvitko BH, Kremer JM, Wang Y, He SY, Tsuda K.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3055-E3064. doi: 10.1073/pnas.1800529115. Epub 2018 Mar 12. Erratum in: Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11564.

13.

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.

Kremer JM, Schiff M, Muram D, Zhong J, Alam J, Genovese MC.

RMD Open. 2018 Jan 13;4(1):e000581. doi: 10.1136/rmdopen-2017-000581. eCollection 2018.

14.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20.

15.

Draft genome of the fungicidal biological control agent Burkholderia anthina strain XXVI.

de Los Santos-Villalobos S, Kremer JM, Parra-Cota FI, Hayano-Kanashiro AC, García-Ortega LF, Gunturu SK, Tiedje JM, He SY, Peña-Cabriales JJ.

Arch Microbiol. 2018 Jul;200(5):803-810. doi: 10.1007/s00203-018-1490-6. Epub 2018 Feb 10.

PMID:
29428982
16.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

17.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

18.

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M.

Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5.

19.

Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1.

20.

Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject.

Ocon A, Peredo-Wende R, Kremer JM, Bhatt BD.

Lupus. 2018 Feb;27(2):347-348. doi: 10.1177/0961203317734921. Epub 2017 Oct 9. No abstract available.

PMID:
28992799

Supplemental Content

Loading ...
Support Center